Back to Search
Start Over
Sustained Low-Density Lipoprotein Cholesterol Lowering With Alirocumab in ODYSSEY OUTCOMES
- Source :
- Journal of the American College of Cardiology. 75:448-451
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- In the ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial, 18,924 patients with a recent acute coronary syndrome (ACS) not at lipid goals despite maximally tolerated statin therapy were randomized to alirocumab or placebo
- Subjects :
- Acute coronary syndrome
medicine.medical_specialty
Time Factors
Low density lipoprotein cholesterol
030204 cardiovascular system & hematology
Antibodies, Monoclonal, Humanized
Placebo
law.invention
03 medical and health sciences
chemistry.chemical_compound
0302 clinical medicine
Randomized controlled trial
law
Internal medicine
Humans
Medicine
030212 general & internal medicine
Acute Coronary Syndrome
Alirocumab
business.industry
Cholesterol
Anticholesteremic Agents
Cholesterol, LDL
medicine.disease
Treatment Outcome
chemistry
Monoclonal
Statin therapy
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Cardiology and Cardiovascular Medicine
business
Follow-Up Studies
Subjects
Details
- ISSN :
- 07351097
- Volume :
- 75
- Database :
- OpenAIRE
- Journal :
- Journal of the American College of Cardiology
- Accession number :
- edsair.doi.dedup.....29151a22cf93f5e34b8a300889f12622